Category Archives: MS Treatment

Pacific Grove, CA (PRWEB) February 03, 2015 Castlewood at Monarch Cove, a premier eating disorder treatment center based in Pacific Grove, California, has announced the appointment of Valerie J. Piacitelli, MSW, LMSW, LMT, to Executive Director. Piacitelli brings over 20 years of social work, leadership and instructional experience to the position and will be responsible for the operational management of the facility. Piacitelli has worked in both treatment and academic environments. Most recently, she served as the Executive Director of Montecatini, a residential treatment and outpatient program for eating disorders in Carlsbad, CA. In this position, she provided operational oversight, staffing supervision, and regulatory compliance for the facility. Concurrently, she served as an Academic Advisor, for Boston Universitys social work program. Previously, Ms. Piacitelli was the Clinical Director for Community Connections, a state based eating disorder treatment center in Phoenix, Arizona, also she acted as the Director of Residential Operations of a licensed therapeutic behavioral health residential treatment center for teens, Program Coordinator for a SMI treatment program, and a therapist providing individual and family counseling for patients with eating and co-occurring disorders. Piacitelli earned her Masters in Social Work from Arizona State University where she graduated Cum Laude. She … Continue reading →

Were encouraged by the outcome of this trial, which showed that rHIgM22 was well-tolerated at all of the dose levels we studied, said Anthony Caggiano, M.D., Ph.D., Acordas Senior Vice President of Research and Development. We are currently developing the protocol for our next Phase 1 clinical trial of rHIgM22. The data from this study will help inform the design of the next trial, which will enroll people with MS who are experiencing an active relapse. This was a multi-center, double-blind, randomized, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of a single dose of rHIgM22 in participants with any type of MS who were clinically stable for at least three months. All participants remained on their existing MS treatment regimens, including disease-modifying therapies. The first part of the study included five cohorts, with each cohort receiving a higher dose of rHIgM22 than the previous one. Each cohort consisted of 10 participants (eight receiving drug, two receiving placebo), who were followed for three months after receiving a single dose of study medication. In the second part of the study, 21 treatment-nave participants were randomized to receive placebo or one of the two highest doses of rHIgM22 from the … Continue reading →

Health News: Fracking support, hope for MS, Golden Rice benefits The latest in health news: The Pennsylvania Environmental Protection Agency releases review on low-risk fracking, a stem cell transplant method provides new ... By: ACSHonTV … Continue reading →

Winnipeg Free Press - PRINT EDITION By: Mary Agnes Welch Posted: 3:00 AM | Comments: | Last Modified: 7:36 AM | Updates HANDOUT / THE CANADIAN PRESS Enlarge Image Dr. Mark Freedman of the Ottawa Hospital Research Institute. Two Canadian research centres are gearing up for a clinical trial to determine whether a type of stem cell can help alleviate the symptoms of multiple sclerosis. In the aftermath of controversy over a costly overseas stem-cell treatment touted by a Winnipeg businessman, 20 Manitobans with multiple sclerosis can now take part in a genuine clinical trial, launched Thursday. The $4.2-million study, the first of its kind in Canada, is being funded by the MS Society at Winnipeg's Health Sciences Centre. It comes after revelations about a local medical researcher, Doug Broeska, whose company Regenetek charged about 70 MS and ALS patients as much as $45,000 for stem-cell treatment at a hospital in India. Earlier this month, controversy erupted over Broeska's credentials, the ethics approvals his research received, promises he made about the treatment's effects and the lack of followup care provided to patients. Broeska, who has been successfully sued several times in relation to past business ventures, claimed to have a … Continue reading →

Winnipeg Free Press - ONLINE EDITION By: Mary Agnes Welch Posted: 01/29/2015 8:55 AM | Comments: | Last Modified: 01/29/2015 7:49 PM | Updates In the wake of controversy over a costly overseas stem cell treatment touted by a Winnipeg businessman, the Multiple Sclerosis Society of Canada is launching a genuine clinical trial open to MS patients in Winnipeg and Ottawa. The MS Society has earmarked $4.2 million for the two-year study. The clinical trial is limited to 20 people in Manitoba and 20 at the Ottawa site. The clinical trial, the first of its kind in Canada, comes after revelations about a local medical researcher, Doug Broeska, who charged about 70 MS and ALS patients as much as $45,000 for stem cell treatment at a hospital in India. Controversy has swirled about his credentials, the ethics approvals his research received, promises he made about the treatments effects and the follow-up care provided to patients. Broeska, who has been successfully sued several times in relation to past business ventures, claimed to have a PhD from the University of Manitoba, which is inaccurate. He later claimed to have a PhD from Brightland University, which charges $3,600 for a PhD certificate available … Continue reading →

BioGen Slide Cup BioGen used this sales aid to educate patients with multiple sclerosis on Tecfidera, a medication used to treat relapsing forms of MS. The cover features an ... By: Structural Graphics … Continue reading →

Just under four years ago, Carman resident Jolene Stevenson travelled to India to undergo Liberation Therapy in the hopes that it would cure her MS. They were thinking that the Liberation treatment is the cure, she remembered. So if it worked there wouldnt be any more symptoms of MS. The treatment and travel costs added up to about $17,000 and the Carman community held a fundraiser to help Stevenson with the expenses, bringing in over $10,000 to help support her trip. Stevensons treatment was arranged through Regenetek Research and she paid the fee through CliniCard Inc. - both companies owned by another Carman resident,DougBroeska,whose credentials came into question earlier this month. Other media organizations have reported that Broeska both fabricated his credentials and overstated the results of the Combination Therapy MS treatment for which he recruited patients. Regenetek Inc. and CliniCard are both located at 1213 Chevrier Boulevard in Winnipeg. Broeskapreviously owned and operated a lumber company called Hardwood Forest Products at the same address. Broeska stated on his LinkedIn profile (now removed) that he graduated with a Bachelor of Science and a Ph.D. from the University of Manitoba, but the university registrars office told the Valley Leader there is … Continue reading →

Stem cell treatment for Multiple Sclerosis - Case study Mr. Scott recover after his suffer from MS for over 10 years. Puhua International Hospital provide stem cell treatment for neurological and neurosurgical dis... By: Puhua Hospital … Continue reading →

SOURCE: Multiple Sclerosis Society of Canada WINNIPEG, MB--(Marketwired - January 23, 2015) - On Thursday, January 29, 2015, the Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation, along with principal investigators Dr. Mark Freedman and Dr. James Marriott, will be announcing a human clinical trial involving a novel stem cell treatment in multiple sclerosis (MS). Canada has the highest rate of MS in the world. MS is a chronic, often disabling disease of the central nervous system comprising the brain, spinal cord and optic nerve. It is one of the most common neurological diseases affecting young adults in Canada. Most people with MS are diagnosed between the ages of 15 and 40, and the unpredictable effects of MS last for the rest of their lives. Media are welcome to attend an event at Health Sciences Centre Winnipeg where Mr. Yves Savoie, president and CEO of the MS Society of Canada, and Dr. James Marriott will announce the details of this landmark study. When:12pm CT, Thursday, January 29, 2015 Interview and photo opportunities will be available with: Where:Courtyard Caf, Health Sciences Centre Winnipeg Magenta Fox Zone, Level 2 800 Sherbrook St. Winnipeg, Manitoba Note: The Courtyard Caf … Continue reading →

Winchester, VA (PRWEB) January 23, 2015 Dr. Jeff Dickson with the Shenandoah Valley Implant Institute is pleased to announce the availability of a state-of-the-art receding gums treatment at his office in Winchester, VA. Patients who have suffered from the devastating effects of periodontal disease can enjoy smiling again thanks to the Pinhole Surgical Technique (PST), a minimally invasive procedure that restores the gum line without incisions or sutures. Gum recession develops in many ways. When an individual does not brush and floss regularly, experiences hormone changes or grinds teeth, receding gums are more likely to occur. Poor oral hygiene also affects the gums, as plaque builds up around the roots of teeth and hardens into calculus. This substance inflames the gums, causing them to pull away from tooth roots. Periodontal disease often results from calculus build-up, so regular brushing, flossing and professional dental cleanings are critical for oral health. Recession may not be immediately obvious because the condition frequently occurs gradually. Symptoms include sensitive teeth, tender gums, a longer tooth line and exposed roots. People who avoid treatment place themselves at risk for periodontal disease as the gaps widen and allow bacteria to become trapped below the gum line. Dentists … Continue reading →